TY - JOUR AU - Knowles, M. A. AU - Hurst, C. D. PY - 2015 DA - 2015// TI - Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity JO - Nat Rev Cancer VL - 15 UR - https://doi.org/10.1038/nrc3817 DO - 10.1038/nrc3817 ID - Knowles2015 ER - TY - JOUR AU - Carballido, E. M. AU - Rosenberg, J. E. PY - 2014 DA - 2014// TI - Optimal treatment for metastatic bladder cancer JO - Curr Oncol Rep VL - 16 UR - https://doi.org/10.1007/s11912-014-0404-2 DO - 10.1007/s11912-014-0404-2 ID - Carballido2014 ER - TY - JOUR AU - Milowsky, M. I. AU - Rumble, R. B. AU - Booth, C. M. AU - Gilligan, T. AU - Eapen, L. J. AU - Hauke, R. J. PY - 2016 DA - 2016// TI - Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.65.9797 DO - 10.1200/JCO.2015.65.9797 ID - Milowsky2016 ER - TY - JOUR AU - Maase, H. AU - Sengelov, L. AU - Roberts, J. T. AU - Ricci, S. AU - Dogliotti, L. AU - Oliver, T. PY - 2005 DA - 2005// TI - Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.07.757 DO - 10.1200/JCO.2005.07.757 ID - Maase2005 ER - TY - JOUR AU - Dash, A. AU - Galsky, M. D. AU - Vickers, A. J. AU - Serio, A. M. AU - Koppie, T. M. AU - Dalbagni, G. PY - 2006 DA - 2006// TI - Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder JO - Cancer VL - 107 UR - https://doi.org/10.1002/cncr.22031 DO - 10.1002/cncr.22031 ID - Dash2006 ER - TY - JOUR AU - Witjes, J. A. AU - Compérat, E. AU - Cowan, N. C. AU - Santis, M. AU - Gakis, G. AU - Lebret, T. PY - 2014 DA - 2014// TI - EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013guidelines JO - Eur Urol VL - 65 UR - https://doi.org/10.1016/j.eururo.2013.11.046 DO - 10.1016/j.eururo.2013.11.046 ID - Witjes2014 ER - TY - JOUR AU - Santis, M. AU - Bellmunt, J. AU - Mead, G. AU - Kerst, J. M. AU - Leahy, M. AU - Maroto, P. PY - 2012 DA - 2012// TI - Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986 JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.37.3571 DO - 10.1200/JCO.2011.37.3571 ID - Santis2012 ER - TY - JOUR AU - Lord, C. J. AU - Ashworth, A. PY - 2012 DA - 2012// TI - The DNA damage response and cancer therapy JO - Nature VL - 481 UR - https://doi.org/10.1038/nature10760 DO - 10.1038/nature10760 ID - Lord2012 ER - TY - JOUR AU - Sancar, A. AU - Lindsey-Boltz, L. A. AU - Unsal-Kaçmaz, K. AU - Linn, S. PY - 2004 DA - 2004// TI - Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints JO - Annu Rev Biochem VL - 73 UR - https://doi.org/10.1146/annurev.biochem.73.011303.073723 DO - 10.1146/annurev.biochem.73.011303.073723 ID - Sancar2004 ER - TY - JOUR AU - Lee, J. H. AU - Paull, T. T. PY - 2005 DA - 2005// TI - ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex JO - Science VL - 308 UR - https://doi.org/10.1126/science.1108297 DO - 10.1126/science.1108297 ID - Lee2005 ER - TY - JOUR AU - Zou, L. AU - Elledge, S. J. PY - 2003 DA - 2003// TI - Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes JO - Science VL - 300 UR - https://doi.org/10.1126/science.1083430 DO - 10.1126/science.1083430 ID - Zou2003 ER - TY - JOUR AU - Bartek, J. AU - Falck, J. AU - Lukas, J. PY - 2001 DA - 2001// TI - CHK2 kinase--a busy messenger JO - Nat Rev Mol Cell Biol VL - 2 UR - https://doi.org/10.1038/35103059 DO - 10.1038/35103059 ID - Bartek2001 ER - TY - JOUR AU - Bartek, J. AU - Lukas, J. PY - 2003 DA - 2003// TI - Chk1 and Chk2 kinases in checkpoint control and cancer JO - Cancer Cell VL - 3 UR - https://doi.org/10.1016/S1535-6108(03)00110-7 DO - 10.1016/S1535-6108(03)00110-7 ID - Bartek2003 ER - TY - JOUR AU - Zabludoff, S. D. AU - Deng, C. AU - Grondine, M. R. AU - Sheehy, A. M. AU - Ashwell, S. AU - Caleb, B. L. PY - 2008 DA - 2008// TI - AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies JO - Mol Cancer Ther VL - 7 UR - https://doi.org/10.1158/1535-7163.MCT-08-0492 DO - 10.1158/1535-7163.MCT-08-0492 ID - Zabludoff2008 ER - TY - JOUR AU - Huang, P. AU - Chubb, S. AU - Hertel, L. W. AU - Grindey, G. B. AU - Plunkett, W. PY - 1991 DA - 1991// TI - Action of 2’,2’-difluorodeoxycytidine on DNA synthesis JO - Cancer Res VL - 51 ID - Huang1991 ER - TY - JOUR AU - Heinemann, V. AU - Xu, Y. Z. AU - Chubb, S. AU - Sen, A. AU - Hertel, L. W. AU - Grindey, G. B. PY - 1992 DA - 1992// TI - Cellular elimination of 2’,2’-difluorodeoxycytidine 5’-triphosphate: a mechanism of self-potentiation JO - Cancer Res VL - 52 ID - Heinemann1992 ER - TY - JOUR AU - Ferreira, C. G. AU - Span, S. W. AU - Peters, G. J. AU - Kruyt, F. A. AU - Giaccone, G. PY - 2000 DA - 2000// TI - Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460 JO - Cancer Res VL - 60 ID - Ferreira2000 ER - TY - JOUR AU - Pinkerneil, M. AU - Hoffmann, M. J. AU - Deenen, R. AU - Köhrer, K. AU - Arent, T. AU - Schulz, W. A. PY - 2016 DA - 2016// TI - Inhibition of class I histone deacetylases 1 and 2 promotes urothelial carcinoma cell death by various mechanisms JO - Mol Cancer Ther VL - 15 UR - https://doi.org/10.1158/1535-7163.MCT-15-0618 DO - 10.1158/1535-7163.MCT-15-0618 ID - Pinkerneil2016 ER - TY - JOUR AU - Chapman, E. J. AU - Hurst, C. D. AU - Pitt, E. AU - Chambers, P. AU - Aveyard, J. S. AU - Knowles, M. A. PY - 2006 DA - 2006// TI - Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway JO - Oncogene VL - 25 UR - https://doi.org/10.1038/sj.onc.1209513 DO - 10.1038/sj.onc.1209513 ID - Chapman2006 ER - TY - JOUR AU - Vallo, S. AU - Michaelis, M. AU - Rothweiler, F. AU - Bartsch, G. AU - Gust, K. M. AU - Limbart, D. M. PY - 2015 DA - 2015// TI - Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics JO - Transl Oncol VL - 8 UR - https://doi.org/10.1016/j.tranon.2015.04.002 DO - 10.1016/j.tranon.2015.04.002 ID - Vallo2015 ER - TY - STD TI - Ormerod MG. Flow cytometry: Royal Microscopical Society microscopy handbooks. 2nd ed. New York: Garland Science; 1999. ID - ref21 ER - TY - JOUR AU - Fichtinger-Schepman, A. M. AU - Veer, J. L. AU - Hartog, J. H. AU - Lohman, P. H. AU - Reedijk, J. PY - 1985 DA - 1985// TI - Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation JO - Biochemistry VL - 24 UR - https://doi.org/10.1021/bi00324a025 DO - 10.1021/bi00324a025 ID - Fichtinger-Schepman1985 ER - TY - JOUR AU - Bonner, W. M. AU - Redon, C. E. AU - Dickey, J. S. AU - Nakamura, A. J. AU - Sedelnikova, O. A. AU - Solier, S. PY - 2008 DA - 2008// TI - GammaH2AX and cancer JO - Nat Rev Cancer VL - 8 UR - https://doi.org/10.1038/nrc2523 DO - 10.1038/nrc2523 ID - Bonner2008 ER - TY - JOUR PY - 2014 DA - 2014// TI - Comprehensive molecular characterization of urothelial bladder carcinoma JO - Nature VL - 507 UR - https://doi.org/10.1038/nature12965 DO - 10.1038/nature12965 ID - ref24 ER - TY - JOUR AU - Liu, Y. AU - Kwiatkowski, D. J. PY - 2015 DA - 2015// TI - Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target JO - Mol Cancer Ther VL - 14 UR - https://doi.org/10.1158/1535-7163.MCT-14-0622-T DO - 10.1158/1535-7163.MCT-14-0622-T ID - Liu2015 ER - TY - JOUR AU - Forbes, S. A. AU - Bindal, N. AU - Bamford, S. AU - Cole, C. AU - Kok, C. Y. AU - Beare, D. PY - 2011 DA - 2011// TI - COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer JO - Nucleic Acids Res VL - 39 UR - https://doi.org/10.1093/nar/gkq929 DO - 10.1093/nar/gkq929 ID - Forbes2011 ER - TY - JOUR AU - Morgan, M. A. AU - Parsels, L. A. AU - Zhao, L. AU - Parsels, J. D. AU - Davis, M. A. AU - Hassan, M. C. PY - 2010 DA - 2010// TI - Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-09-3573 DO - 10.1158/0008-5472.CAN-09-3573 ID - Morgan2010 ER - TY - JOUR AU - Sampath, D. AU - Rao, V. A. AU - Plunkett, W. PY - 2003 DA - 2003// TI - Mechanisms of apoptosis induction by nucleoside analogs JO - Oncogene VL - 22 UR - https://doi.org/10.1038/sj.onc.1207229 DO - 10.1038/sj.onc.1207229 ID - Sampath2003 ER - TY - JOUR AU - Zannini, L. AU - Delia, D. AU - Buscemi, G. PY - 2014 DA - 2014// TI - CHK2 kinase in the DNA damage response and beyond JO - J Mol Cell Biol VL - 6 UR - https://doi.org/10.1093/jmcb/mju045 DO - 10.1093/jmcb/mju045 ID - Zannini2014 ER - TY - JOUR AU - Kohn, E. A. AU - Yoo, C. J. AU - Eastman, A. PY - 2003 DA - 2003// TI - The protein kinase C inhibitor Gö6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints JO - Cancer Res VL - 63 ID - Kohn2003 ER - TY - JOUR AU - Takai, H. AU - Tominaga, K. AU - Motoyama, N. AU - Minamishima, Y. A. AU - Nagahama, H. AU - Tsukiyama, T. PY - 2000 DA - 2000// TI - Aberrant cell cycle checkpoint function and early embryonic death in Chk1(−/−) mice JO - Genes Dev VL - 14 ID - Takai2000 ER - TY - JOUR AU - Liu, Q. AU - Guntuku, S. AU - Cui, X. S. AU - Matsuoka, S. AU - Cortez, D. AU - Tamai, K. PY - 2000 DA - 2000// TI - Chk1 is an essential kinase that is regulated by Atr and required for the G2/M DNA damage checkpoint JO - Genes Dev VL - 14 UR - https://doi.org/10.1101/gad.840500 DO - 10.1101/gad.840500 ID - Liu2000 ER - TY - JOUR AU - Chen, Z. AU - Xiao, Z. AU - Chen, J. AU - Ng, S. C. AU - Sowin, T. AU - Sham, H. PY - 2003 DA - 2003// TI - Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint JO - Mol Cancer Ther VL - 2 ID - Chen2003 ER - TY - JOUR AU - Bartkova, J. AU - Horejsí, Z. AU - Koed, K. AU - Krämer, A. AU - Tort, F. AU - Zieger, K. PY - 2005 DA - 2005// TI - DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis JO - Nature VL - 434 UR - https://doi.org/10.1038/nature03482 DO - 10.1038/nature03482 ID - Bartkova2005 ER - TY - JOUR AU - Wang, W. T. AU - Catto, J. W. AU - Meuth, M. PY - 2015 DA - 2015// TI - Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors JO - Oncogene VL - 34 UR - https://doi.org/10.1038/onc.2014.221 DO - 10.1038/onc.2014.221 ID - Wang2015 ER - TY - JOUR AU - Kawabe, T. PY - 2004 DA - 2004// TI - G2 checkpoint abrogators as anticancer drugs JO - Mol Cancer Ther VL - 3 ID - Kawabe2004 ER - TY - JOUR AU - Zhou, B. B. AU - Bartek, J. PY - 2004 DA - 2004// TI - Targeting the checkpoint kinases: chemosensitization versus chemoprotection JO - Nat Rev Cancer VL - 4 UR - https://doi.org/10.1038/nrc1296 DO - 10.1038/nrc1296 ID - Zhou2004 ER - TY - JOUR AU - Castedo, M. AU - Perfettini, J. L. AU - Roumier, T. AU - Andreau, K. AU - Medema, R. AU - Kroemer, G. PY - 2004 DA - 2004// TI - Cell death by mitotic catastrophe: a molecular definition JO - Oncogene VL - 23 UR - https://doi.org/10.1038/sj.onc.1207528 DO - 10.1038/sj.onc.1207528 ID - Castedo2004 ER - TY - JOUR AU - Sausville, E. AU - LoRusso, P. AU - Carducci, M. AU - Carter, J. AU - Quinn, M. F. AU - Malburg, L. PY - 2014 DA - 2014// TI - Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors JO - Cancer Chemother Pharmacol VL - 73 UR - https://doi.org/10.1007/s00280-014-2380-5 DO - 10.1007/s00280-014-2380-5 ID - Sausville2014 ER - TY - JOUR AU - Dutto, I. AU - Tillhon, M. AU - Cazzalini, O. AU - Stivala, L. A. AU - Prosperi, E. PY - 2015 DA - 2015// TI - Biology of the cell cycle inhibitor p21(CDKN1A): molecular mechanisms and relevance in chemical toxicology JO - Arch Toxicol VL - 89 UR - https://doi.org/10.1007/s00204-014-1430-4 DO - 10.1007/s00204-014-1430-4 ID - Dutto2015 ER - TY - JOUR AU - Mauro, M. AU - Rego, M. A. AU - Boisvert, R. A. AU - Esashi, F. AU - Cavallo, F. AU - Jasin, M. PY - 2012 DA - 2012// TI - p21 promotes error-free replication-coupled DNA double-strand break repair JO - Nucleic Acids Res VL - 40 UR - https://doi.org/10.1093/nar/gks612 DO - 10.1093/nar/gks612 ID - Mauro2012 ER - TY - JOUR AU - Hong, D. AU - Infante, J. AU - Janku, F. AU - Jones, S. AU - Nguyen, L. M. AU - Burris, H. PY - 2016 DA - 2016// TI - Phase I study of LY2606368, a checkpoint kinase 1 inhibitor, in patients with advanced cancer JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.64.5788 DO - 10.1200/JCO.2015.64.5788 ID - Hong2016 ER - TY - JOUR AU - Daud, A. I. AU - Ashworth, M. T. AU - Strosberg, J. AU - Goldman, J. W. AU - Mendelson, D. AU - Springett, G. PY - 2015 DA - 2015// TI - Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.57.5027 DO - 10.1200/JCO.2014.57.5027 ID - Daud2015 ER - TY - JOUR AU - Parsels, L. A. AU - Qian, Y. AU - Tanska, D. M. AU - Gross, M. AU - Zhao, L. AU - Hassan, M. C. PY - 2011 DA - 2011// TI - Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-10-3082 DO - 10.1158/1078-0432.CCR-10-3082 ID - Parsels2011 ER - TY - JOUR AU - Itamochi, H. AU - Nishimura, M. AU - Oumi, N. AU - Kato, M. AU - Oishi, T. AU - Shimada, M. PY - 2014 DA - 2014// TI - Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary JO - Int J Gynecol Cancer VL - 24 UR - https://doi.org/10.1097/IGC.0000000000000014 DO - 10.1097/IGC.0000000000000014 ID - Itamochi2014 ER -